Ocugen's Dual Track: Bahamian Approval, Phase 3 Progress, and a Shareholder Vote on Hold

Ocugen's OCU400 gets preliminary Bahamas approval and OCU410 data is presented, but a shareholder vote on 250M new shares was postponed.

Ocugen is running two races at once — one against retinal degeneration, the other against its own capital structure. This week delivered movement on both fronts, though only one of them produced anything resembling a market cheer.

The Plymouth Meeting, Pennsylvania-based gene therapy developer confirmed that the Longevity and Regenerative Therapies Board of the Bahamas has granted preliminary approval and priority status to OCU400, its investigational treatment for retinitis pigmentosa. The company intends to make the therapy available through an expanded access program, with plans to treat the first patient within 90 days of securing full authorization. For a developer of novel therapies, such overseas regulatory pathways offer a chance to accumulate real-world treatment experience while the slower approval machinery in core markets grinds on.

That announcement landed Friday alongside a separate clinical milestone. Dr. Raj K. Maturi presented 12-month data from the Phase 2 ArMaDa trial of OCU410 — a gene therapy targeting geographic atrophy, the advanced stage of dry age-related macular degeneration — at the 59th annual meeting of the Retina Society. The condition remains one for which treatment options are severely limited, and Ocugen is betting that a novel gene-therapy mechanism can slow lesion progression in affected patients.

From Phase 2 Data to Phase 3 Dosing

The Retina Society presentation arrives during a stretch of heightened clinical activity for the OCU410 program. Roughly two weeks earlier, the first patient was dosed in ArMaDa3, the global Phase 3 registrational study. A second indication for the same candidate is advancing in parallel: earlier this month, Ocugen reported that an independent Data Monitoring Committee had completed an interim review of the Phase 2/3 OCU410ST study. That assessment covered 26 subjects — 16 treated participants and 10 controls — across an eight-month observation window.

Management has been working the conference circuit to keep the pipeline narrative in front of investors. CEO Dr. Shankar Musunuri represented the company at the Citi Biopharma Conference on September 9 and at H.C. Wainwright's investor conference in New York City on September 15, walking through the current state of the development pipeline in moderated sessions.

The Vote That Didn't Happen

Against that clinical backdrop, the equity told a different story. Shares closed Friday at EUR 0.9130, a gain of 2.2% on the day — a modest stabilization that still leaves the stock 61% below its 52-week high of EUR 2.35.

The restraint is not hard to trace. At a special meeting on Monday, shareholders voted to postpone balloting on a proposed authorization of 250,000,000 additional shares. Only 160,214,431 shares were represented, equal to 47.3% of the common stock outstanding as of the July 27, 2026 record date. Skepticism had already been stoked by an insider sale by the CEO roughly a month earlier.

The standoff captures the familiar bind of capital-intensive biotech: without fresh equity, expensive clinical research is difficult to finance through to market readiness, yet every new tranche threatens meaningful dilution for existing holders.

Treating rare ocular diseases like retinitis pigmentosa remains a field of genuine scientific promise. But until Ocugen secures shareholder consent for its capital measures, even a regulatory breakthrough in the Bahamas offers only limited comfort to the share price. For investors, attention now shifts to execution on the Phase 3 study and the readout of complete data sets later in the year.